{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:42:03Z","timestamp":1789670523557,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15207-4","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:01:13Z","timestamp":1764943273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic relevance of increased tumor-infiltrating lymphocytes in residual TNBC following neoadjuvant chemotherapy"],"prefix":"10.1186","volume":"25","author":[{"given":"Nathalia Cruz","family":"da Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Cauduro Ponso","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Pires Souto","family":"Damin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"15207_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-020-07050-x","volume":"20","author":"X Li","year":"2020","unstructured":"Li X, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:564. https:\/\/doi.org\/10.1186\/s12885-020-07050-x.","journal-title":"BMC Cancer"},{"key":"15207_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41416-019-0657-6","volume":"122","author":"Y Mao","year":"2020","unstructured":"Mao Y, et al. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. Br J Cancer. 2020;122:489\u2013500. https:\/\/doi.org\/10.1038\/s41416-019-0657-6.","journal-title":"Br J Cancer"},{"key":"15207_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-016-4072-9","volume":"161","author":"YR Chung","year":"2017","unstructured":"Chung YR, Kim HJ, Jang MH, Park SY. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017;161:409\u201320. https:\/\/doi.org\/10.1007\/s10549-016-4072-9.","journal-title":"Breast Cancer Res Treat"},{"key":"15207_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"C Denkert","year":"2019","unstructured":"Denkert C, et al. Tumour-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer: a pooled analysis of 3771 patients. Ann Oncol. 2019;30:236\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdy540.","journal-title":"Ann Oncol"},{"key":"15207_CR5","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3390\/cancers12103038","volume":"12","author":"L Wang","year":"2020","unstructured":"Wang L, et al. Abundant regulatory T cell (Treg) as a predictive biomarker for neoadjuvant chemotherapy in triple-negative breast cancer. Cancers (Basel). 2020;12:3038. https:\/\/doi.org\/10.3390\/cancers12103038.","journal-title":"Cancers (Basel)"},{"key":"15207_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13058-023-01633-z","volume":"25","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. FOXP3\u2009+\u2009tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2023;25:14. https:\/\/doi.org\/10.1186\/s13058-023-01633-z.","journal-title":"Breast Cancer Res"},{"key":"15207_CR7","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/annonc\/mdu148","volume":"25","author":"R Salgado","year":"2014","unstructured":"Salgado R, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2014;25:1857\u201372. https:\/\/doi.org\/10.1093\/annonc\/mdu148.","journal-title":"Ann Oncol"},{"key":"15207_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000528","volume":"8","author":"P Jaime-Sanchez","year":"2020","unstructured":"Jaime-Sanchez P, Uranga-Murillo I, Aguilo N, Khouili SC, Arias MA, Sancho D, et al. Cell death induced by cytotoxic CD8\u2009+\u2009T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens. J Immunother Cancer. 2020;8:e000528. https:\/\/doi.org\/10.1136\/jitc-2020-000528.","journal-title":"J Immunother Cancer"},{"key":"15207_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00821-z","volume":"11","author":"N Riaz","year":"2025","unstructured":"Riaz N, Chen BE, Bane A, et al. Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial. NPJ Breast Cancer. 2025;11:97. https:\/\/doi.org\/10.1038\/s41523-025-00821-z.","journal-title":"NPJ Breast Cancer"},{"key":"15207_CR10","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32:1236\u201344. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.007.","journal-title":"Ann Oncol"},{"key":"15207_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre RA, Jonas SF, Salgado R, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331:1135\u201344. https:\/\/doi.org\/10.1001\/jama.2024.3056.","journal-title":"JAMA"},{"key":"15207_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.breast.2022.10.001","volume":"66","author":"S Li","year":"2022","unstructured":"Li S, Zhang Y, Zhang P, Xue S, Chen Y, Sun L, et al. Predictive and prognostic values of tumor-infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: a meta-analysis. Breast. 2022;66:97\u2013109. https:\/\/doi.org\/10.1016\/j.breast.2022.10.001.","journal-title":"Breast"},{"key":"15207_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.breast.2024.01.005","volume":"73","author":"S Li","year":"2024","unstructured":"Li S, Zhang Y, Zhang P, Xue S, Chen Y, Sun L, Yang R. Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis. Breast. 2024;73:102\u201311. https:\/\/doi.org\/10.1016\/j.breast.2024.01.005.","journal-title":"Breast"},{"key":"15207_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"SJ Luen","year":"2019","unstructured":"Luen SJ, et al. Prognostic implications of residual disease TILs and residual cancer burden in TNBC after NAC. Ann Oncol. 2019;30:236\u201342. https:\/\/doi.org\/10.1093\/annonc\/mdy540.","journal-title":"Ann Oncol"},{"key":"15207_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6668-z","volume":"20","author":"G Gao","year":"2020","unstructured":"Gao G, Wang Z, Qu X, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:179. https:\/\/doi.org\/10.1186\/s12885-020-6668-z.","journal-title":"BMC Cancer"},{"key":"15207_CR16","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1002\/cam4.4304","volume":"10","author":"J Hong","year":"2021","unstructured":"Hong J, Rui W, Fei X, Chen X, Shen K. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Med. 2021;10:7921\u201333. https:\/\/doi.org\/10.1002\/cam4.4304.","journal-title":"Cancer Med"},{"key":"15207_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092148","volume":"14","author":"DJ Fassler","year":"2022","unstructured":"Fassler DJ, Torre-Healy LA, Gupta R, et al. Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression. Cancers (Basel). 2022;14:2148. https:\/\/doi.org\/10.3390\/cancers14092148.","journal-title":"Cancers (Basel)"},{"key":"15207_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01282-8","volume":"15","author":"Y Tie","year":"2022","unstructured":"Tie Y, Tang F, Wei YQ, et al. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15:61. https:\/\/doi.org\/10.1186\/s13045-022-01282-8.","journal-title":"J Hematol Oncol"},{"key":"15207_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/SLA.0000000000005954","volume":"278","author":"R Wu","year":"2023","unstructured":"Wu R, Oshi M, Asaoka M, et al. Intratumoral tumor-infiltrating lymphocytes are associated with cell proliferation and better survival but not always with chemotherapy response in breast cancer. Ann Surg. 2023;278:587\u201397. https:\/\/doi.org\/10.1097\/SLA.0000000000005954.","journal-title":"Ann Surg"},{"key":"15207_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106556","volume":"187","author":"X Chang","year":"2023","unstructured":"Chang X, Bian M, Liu L, et al. Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacol Res. 2023;187:106556. https:\/\/doi.org\/10.1016\/j.phrs.2022.106556.","journal-title":"Pharmacol Res"},{"key":"15207_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2120676","volume":"11","author":"R Barnestein","year":"2022","unstructured":"Barnestein R, Galland L, Kalfeist L, et al. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. Oncoimmunology. 2022;11:2120676. https:\/\/doi.org\/10.1080\/2162402X.2022.2120676.","journal-title":"Oncoimmunology"},{"key":"15207_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tbcr-23-43","volume":"5","author":"ML Rosa","year":"2023","unstructured":"Rosa ML, Reinert T, Pauletto MM, et al. Implications of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer: clinical oncologist perspectives. Transl Breast Cancer Res. 2023;5:4. https:\/\/doi.org\/10.21037\/tbcr-23-43.","journal-title":"Transl Breast Cancer Res"},{"key":"15207_CR23","doi-asserted-by":"publisher","first-page":"648139","DOI":"10.3389\/fonc.2021.648139","volume":"11","author":"H Yi","year":"2021","unstructured":"Yi H, Li X, Tan F, Fu Y, Tang S, Deng T. Immune checkpoint Inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. 2021;11:648139. https:\/\/doi.org\/10.3389\/fonc.2021.648139.","journal-title":"Front Oncol"},{"key":"15207_CR24","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","volume":"15","author":"F Lynce","year":"2024","unstructured":"Lynce F, Mainor C, Donahue RN, et al. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL phase II study. Nat Commun. 2024;15:2691. https:\/\/doi.org\/10.1038\/s41467-024-46961-x.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15207-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15207-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15207-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T14:01:14Z","timestamp":1764943274000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15207-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15207"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15207-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Research Ethics Committee (CEP-HCPA) of the Hospital de Cl\u00ednicas de Porto Alegre under CAAE number 25580319.9.0000.5327 and approval number 3.806.481, in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments.The requirement for informed consent was formally waived by the Ethics Committee, based on item IV.5.e of Resolution CNS 466\/12, which allows waiver of consent in retrospective studies using previously collected biological materials, provided that participants are not exposed to risk and that all data are anonymized.All histological samples analyzed in this study were archival materials originally collected for diagnostic purposes, and all data were fully anonymized prior to analysis. However, for patients who remained under active clinical follow-up during data collection, written informed consent was obtained accordingly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1856"}}